Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2023-06-23

FDA Approved: AMLODIPINE BESYLATE AND OLMESARTAN MEDOXOMIL — Supplemental Application (Ajanta Pharma USA Inc.)

View source ↗

Summary

FDA approved a supplemental application to add a fixed-dose combination of amlodipine besylate and olmesartan medoxomil from Ajanta Pharma USA Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Amlodipine Besylate and Olmesartan Medoxomil (amlodipine besylate and olmesartan medoxomil)

Snippet

SUPPL AP for AMLODIPINE BESYLATE AND OLMESARTAN MEDOXOMIL (AMLODIPINE BESYLATE AND OLMESARTAN MEDOXOMIL)